The Clinical Oncology Society of Australia (COSA) SIGNETURe Neuroendocrine Tumor (NET) Registry of Australia: First Report of Patient Characteristics and Patterns of Care Abstract #1073

Introduction: NETs remain a relatively rare malignancy. Clinical trials are often hindered by the limited number of patients available and thus registries provide important information about patterns of care and patient outcomes.
Aim(s): With this in mind the SIGNETURe registry was developed to record patient characteristics, therapies used and outcomes for patients with NETs in Australia.
Materials and methods: Patients seen at specialist NET referral centres were offered participation in the registry. Both newly diagnosed cases (incident cases) and those with a prior established diagnosis (prevalent cases) were included. The registry was reviewed by an appropriate Ethics committee in each state of Australia. An electronic web based database was used for data collection (DATATRAK©).
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: A/Prof Timothy Price
Keywords: Registry

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2901 Data is Power - Registry Experience at an ENETS COE
Introduction: The collection of anonymised data for patients with neuroendocrine tumours is necessary for the ongoing improvement of patient care and research/clinical trials.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Annette Hogg
Authors: Hogg A, Stell A, Marusic P, Sinnott R, ...
#2713 The Economic Impact to Patients with Neuroendocrine Tumours
Introduction: The quality of life impact on patients with neuroendocrine tumours (NETs) and the economic burden on health systems are substantial. However, little is known about the economic burden to individual patients and families for medical out-of-pocket expenses and employment decisions.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: Assoc Prof David Wyld
Authors: Wyld D, Elliott T, Wakelin K, Leyden S, ...
#3051 Epidemiology, Pathological and Clinical Features of 4307 Patients with Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NEN) of the Spanish Neuroendocrine Cancer Registry (R-GETNE)
Introduction: RGETNE national NEN Registry comprises 74 hospitals from all regions of Spain.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Prof. Rocio Garcia Carbonero
#702 Observational Study of Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors in Argentina: Results from the Large Database of a Multidisciplinary Group. Clinical Multicenter Study
Introduction: Neuroendocrine tumors (NETs) consist of a spectrum of malignancies that can arise from neuroendocrine cells throughout the body.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Juan Manuel O'Connor
#1158 A Phase II Study of Everolimus in Patients with FDG-PET Positive Intermediate Grade (Ki67 3-20%) Pancreatic Neuroendocrine Tumor
Introduction: The RADIANT-3 trial showed Everolimus (EV), as active in patients (pts) with progressive well/intermediate grade PNETs. Intermediate/grade 2 (Ki67 3-20%) PNETs have variable biology. FDG-PET avidity is an independent negative factor for survival, consistent with aggressive disease biology- but such imaging is not used to select treatment as in the case of the RADIANT 3 trial.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: ASSOC PROF Michael Michael
Authors: Michael M, Pavlakis N, Wyld D, Link E, ...
Keywords: everolimus, FDG-PET